Physician profile
Terri Compton
NPI 1144376609
$2,086.13
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $65.86 · 2023: $547 · 2024: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $418.59 | 2023-2024 | Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $388.78 | 2023-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $286.14 | 2022-2024 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $245.38 | 2023-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $182.15 | 2024 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $136.42 | 2022-2024 | Austedo Xr |
| Abbvie INC. | $83.60 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $66.87 | 2024 | Fasenra |
| Alkermes, INC. | $64.90 | 2023-2024 | Aristada, Lybalvi |
| Indivior INC. | $55.47 | 2023-2024 | Perseris, Sublocade |
| Braeburn INC. | $46.41 | 2023 | Brixadi |
| Vanda Pharmaceuticals INC. | $36.78 | 2024 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.23 | 2023-2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $25.02 | 2024 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $22.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Compton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.